EVUSHELD is a combination of two long-acting monoclonal antibodies (LAAB) and is the only antibody therapy authorized in the U.S. for pre exposure prophylactic (preventive) use against COVID-19 in immunocompromised patients.
EVUSHELD therapy is administered in two quick intramuscular doses and provides up to a 77% reduction in the risk of COVID-19 infection for 6 months after administration.
You MUST meet the following criteria to be eligible for EVUSHELD treatment:
- 12 years of age or older
- Weigh at least 88 pounds (40 kg)
- Not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2
- Have not received a COVID-19 vaccine within the last 2 weeks
- Have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccine
- OR that any vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID- vaccine ingredient.